Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00138762 · ClinicalTrials.gov registry record · Phase 3
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,800
- Enrollment target
NCT00138762 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 3,800 participants.
The verdict
NCT00138762, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,800 participants
- Enrollment target
Study Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
Interventions
- DRUG placebo
- DRUG atorvastatin
- DRUG torcetrapib/atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,800 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00138762
The ClinicalTrials.gov registry entry for NCT00138762 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00138762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00138762 about?
NCT00138762 is a clinical study titled "A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
What is the current status of trial NCT00138762?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,800 participants. The study started on 2004-07. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00138762?
The interventions under investigation include: placebo (DRUG), atorvastatin (DRUG), torcetrapib/atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00138762?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.